FDA asks COVID vaccine makers to target KP.2 strain, if feasible, for next shot
GAITHERSBURG, Md., June 14, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from the U.S. FDA, European Medicines Agency (EMA) and the World Health Organization (WHO) to target the JN.1 lineage this fall.1-3
The FDA’s Center for Biologics Evaluation and Research held a meeting with the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on 5 June to discuss necessary changes to the country’s Covid-19 vaccines from 2024 to 2025. The committee voted unanimously to update the currently available Covid-19 vaccines to target the JN.1 variant. The VRBPAC has previously made several recommendations for different formulations of Covid-19 vaccines.
GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
As some industry efforts to deliver vaccines to Africa have fallen by the wayside, Serum Institute of India (SII), together with the U.K.’s University of Oxford and U.S.-based Novavax, are making good on their pledge.
May 20 (Reuters) - Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's (NVAX.O), opens new tab board, after the COVID-19 vaccine maker struck a licensing deal with Sanofi (SASY.PA), opens new tab.
Novavax`s license deal with Sanofi at lofty valuation sends shares soaring
GAITHERSBURG, Md., May 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).
GAITHERSBURG, Md., May 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2024.